HAGAR develops GWave, a non-invasive continuous glucose monitor that uses radio-frequency (RF) waves to measure blood glucose in real time rather than interstitial fluid. The device integrates with Bluetooth and smartphones and includes an automated alert system for significant glucose fluctuations. In a proprietary study at the Weizmann Institute of Science (n=75) GWave achieved a mean MARD of 6.7%, with 97% of points in Zone A and 3% in Zone B on the Clarke Error Grid. The study included 34 people with diabetes (82% Type 1), ten pregnant people with diabetes, and 31 without diabetes; monitoring was performed on the wrist and compared to BGM and two commercial CGMs. A hypoglycemic test with Dr. Irl Hirsch demonstrated the device tracked a drop from 180 to 46 mg/dL accurately. HAGAR holds an FDA Breakthrough Device Designation (2021) and plans additional U.S. and Israeli studies in late 2023, aiming for eventual smartwatch integration at low cost to broaden access. HAGAR's core product, GWave, is described as the world’s first non-invasive continuous glucose monitor that uses radio-frequency (RF) waves to measure blood glucose rather than interstitial fluid. The company says GWave yields over 90% detection rates and clinical testing cited greater than 95% accuracy in at least one trial. GWave First Generation is about a third of the size of a smartphone, uses less RF than a smartphone, and connects to a smartphone app for readings. The company is developing GWave 2.0 as a sensor that can be integrated into a smartwatch and linked to the existing app to share data with healthcare providers. HAGAR positions the device both for diabetes management and preventive care to detect elevated glucose before diagnosis. Financially, the company has raised capital to support development and regulatory work, including a recent Series B that increases its total funding.

Total raised

$17M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2023